These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 9183308)

  • 21. The effect of dexfenfluramine on eating habits in a Dutch ambulatory android overweight population with an overconsumption of snacks.
    Drent ML; Zelissen PM; Koppeschaar HP; Nieuwenhuyzen Kruseman AC; Lutterman JA; van der Veen EA
    Int J Obes Relat Metab Disord; 1995 May; 19(5):299-304. PubMed ID: 7647820
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term weight loss with sibutramine: a randomized controlled trial.
    Wirth A; Krause J
    JAMA; 2001 Sep; 286(11):1331-9. PubMed ID: 11560538
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial.
    Sánchez-Reyes L; Fanghänel G; Yamamoto J; Martínez-Rivas L; Campos-Franco E; Berber A
    Clin Ther; 2004 Sep; 26(9):1427-35. PubMed ID: 15531005
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Somatometric and hormonal effects of dexfenfluramine.
    Sonka J; Marek J; Svacina S; Sucharda P; Stĕpán J
    Sb Lek; 1995; 96(4):299-301. PubMed ID: 8711372
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dexfenfluramine in the treatment of severe obesity: a placebo-controlled investigation of the effects on weight loss, cardiovascular risk factors, food intake and eating behaviour.
    Mathus-Vliegen EM; van de Voorde K; Kok AM; Res AM
    J Intern Med; 1992 Aug; 232(2):119-27. PubMed ID: 1506807
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term effect of dexfenfluramine on amino acid profiles and food selection in obese patients during weight loss.
    Breum L; Møller SE; Andersen T; Astrup A
    Int J Obes Relat Metab Disord; 1996 Feb; 20(2):147-53. PubMed ID: 8646251
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of fenfluramine and dexfenfluramine in the treatment of obesity: a meta-analysis.
    Carvajal A; García del Pozo J; Martín de Diego I; Rueda de Castro AM; Velasco A
    Methods Find Exp Clin Pharmacol; 2000 Jun; 22(5):285-90. PubMed ID: 11031729
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A close look at fenfluramine and dexfenfluramine.
    Vivero LE; Anderson PO; Clark RF
    J Emerg Med; 1998; 16(2):197-205. PubMed ID: 9543401
    [TBL] [Abstract][Full Text] [Related]  

  • 29. X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance.
    Toplak H; Ziegler O; Keller U; Hamann A; Godin C; Wittert G; Zanella MT; Zúñiga-Guajardo S; Van Gaal L
    Diabetes Obes Metab; 2005 Nov; 7(6):699-708. PubMed ID: 16219013
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Psychobehavioral and nutritional predictors of weight loss in obese women treated with sibutramine.
    Hainer V; Kunesova M; Bellisle F; Hill M; Braunerova R; Wagenknecht M
    Int J Obes (Lond); 2005 Feb; 29(2):208-16. PubMed ID: 15583700
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of dexfenfluramine in a weight loss program for obese infertile women.
    Galletly C; Clark A; Tomlinson L
    Int J Eat Disord; 1996 Mar; 19(2):209-12. PubMed ID: 8932560
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of a new anorectic agent AN 448 with fenfluramine in the treatment of refractory obesity.
    Goldrick RB; Nestel PJ; Havenstein N
    Med J Aust; 1974 Jun; 1(22):882-5. PubMed ID: 4604249
    [No Abstract]   [Full Text] [Related]  

  • 33. Dexfenfluramine treatment of obesity: a double blind trial with post trial follow up.
    O'Connor HT; Richman RM; Steinbeck KS; Caterson ID
    Int J Obes Relat Metab Disord; 1995 Mar; 19(3):181-9. PubMed ID: 7780494
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Effectiveness of serotonergic agonists in the treatment of obese patients].
    Mendoza Espejo R; Díaz Pérez de Madrid J; Buitrago F
    Aten Primaria; 1995 Oct; 16(6):364-6. PubMed ID: 7488690
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lower dosages of phentermine-fenfluramine given in the afternoon: five cases with significant weight loss.
    Katz DA; Maloney MJ; Sutkamp JC; McConville BJ
    Int J Eat Disord; 1999 May; 25(4):469-74. PubMed ID: 10202659
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of hypocaloric diet with and without D-fenfluramine treatment on growth hormone release after growth hormone-releasing factor stimulation in patients with android obesity.
    Medeiros-Neto G; Lima N; Perozim L; Pedrinola F; Wajchenberg BL
    Metabolism; 1994 Aug; 43(8):969-73. PubMed ID: 8052154
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Iowa patients want new anti-obesity drug.
    Belling W
    Iowa Med; 1996 Sep; 86(7):278-9. PubMed ID: 8854575
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Is it possible to obtain a reduction of body weight exclusively via a loss in fat mass? Experience with d-fenfluramine].
    Del Ponte A; D'Orazio N; Di Giacomo G; Tritella T; Bitti G; Martines G
    Recenti Prog Med; 1993 Feb; 84(2):100-5. PubMed ID: 8465086
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term efficacy of fenfluramine in treatment of obesity.
    Douglas JG; Gough J; Preston PG; Frazer I; Haslett C; Chalmers SR; Munro JF
    Lancet; 1983 Feb; 1(8321):384-6. PubMed ID: 6130379
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Appraisal of the clinical value of serotoninergic drugs.
    Munro JF; Scott C; Hodge J
    Am J Clin Nutr; 1992 Jan; 55(1 Suppl):189S-192S. PubMed ID: 1728833
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.